Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 7/20 | 0.60 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4304875 | 1.00 | — | — | |
| SCHEMBL311448 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL10425368 | 0.95 | — | — | |
| SCHEMBL17238725 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL2183500 | 0.95 | TBXAS1 (0.60) | TBXAS1EGLN3CYP19A1PRKCIALDH1A1 | |
| Bromide SCHEMBL28608395 | 0.86 | TBXAS1 (0.68) | TBXAS1EGLN3CYP19A1PRKCI | |
| Bromide SCHEMBL18941395 | 0.85 | TBXAS1 (0.72) | TBXAS1PRKCI | |
| SCHEMBL9253280 | 0.84 | TBXAS1 (0.71) | TBXAS1EGLN3CYP19A1PRKCI | |
| SCHEMBL78110 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL4781930 | 0.82 | TBXAS1 (0.68) | TBXAS1CYP19A1PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003214-B | Substituted pyrazolo [1,5-a ] pyrimidine compounds as TRK kinase inhibitors | 阵列生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharm Inc. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180263984-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-09-20 | — | — | US | disclosed |
| EP-3299372-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OFSUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2451812-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9796724-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2451812-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1791845-A2 | FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS | AMGEN INC. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006130160-A2 | FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS | AMGEN INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | LCK, NFATC1, MINK1 | TBXAS1 377/4885EGLN3 4381/4885CYP19A1 644/4885 |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | TBXAS1 530/4885EGLN3 3506/4885CYP19A1 3062/4885 |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | TXK, FRK, LTK | TBXAS1 530/4885EGLN3 3506/4885CYP19A1 3062/4885 |
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | TBXAS1 530/4885EGLN3 3506/4885CYP19A1 3062/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | TBXAS1 510/4885EGLN3 3457/4885CYP19A1 2914/4885 |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | TXK, FRK, LTK | TBXAS1 530/4885EGLN3 3506/4885CYP19A1 3062/4885 |
| US-20180263984-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | TBXAS1 530/4885EGLN3 3506/4885CYP19A1 3062/4885 |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | LTK, TXK, FRK | TBXAS1 568/4885EGLN3 3543/4885CYP19A1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.